Elucid Raises $55 Million in Series D Funding
Elucid, a Boston-based medical technology company, has announced the completion of a $55 million Series D funding round. The company specializes in developing Plaque-IQ™, an FDA-cleared software that quantifies coronary and carotid plaque morphology using non-invasive CT scans.
Investors and Leadership
The Series D round saw participation from investors including IAG Capital Partners, Elevage Medical Technologies, and an undisclosed strategic investor. Kelly Huang, PhD, serves as the President and CEO of Elucid, guiding the company as it continues to innovate in the medical imaging space.
Use of Funds
While specific plans for the newly raised funds have not been detailed, it is anticipated that Elucid will use this capital to further develop and expand its Plaque-IQ™ software. This could include enhancements to the software's capabilities, broadening its application in clinical settings, and possibly expanding the company's market reach.
About Elucid
Elucid's Plaque-IQ™ software is a significant tool in the medical field, offering a non-invasive method for analyzing plaque morphology. This advancement aids healthcare providers in better understanding and treating coronary and carotid conditions.
The recent funding is expected to bolster Elucid's efforts in providing cutting-edge solutions for improved patient outcomes.